Sanofi Aventis Germany
Tel: 0180 / 2 222010
The Sanofi-Aventis Deutschland GmbH is the German subsidiary of one of the world’s leading pharmaceutical companies. The Group employs approximately 100,000 employees worldwide and maintains strong market positions in the regions of North America, Europe and Asia. Its core business is the original innovative prescription drugs for the treatment (drugs) and prevention (vaccines) of serious, widespread diseases. The R & D expenditures by sanofi-aventis in 2008 amounted to 4.6 billion euros, of which, the Sanofi-Aventis Deutschland GmbH about 600 million euros worn. But not only the high use of resources is decisive – the research from sanofi-aventis is one of the most productive and successful worldwide. Currently, sanofi-aventis 65 novel drugs and vaccines in development. Of these 27 projects are in advanced clinical stage III or in the admission process. The focus is on seven core therapeutic areas: diabetes / metabolism, cardiovascular, thrombosis, central nervous system, internal medicine, oncology and vaccines. In Germany, one of sanofi-aventis with sales (including export) of 4.0 billion euros of the leading providers of innovative medicines.